Business Wire Feed
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
If approved, sonrotoclax will become the first BCL2 inhibitor for R/R MCL in the U.S., addressing a high unmet need in an aggressive cancer Sonrotoclax previously received Breakthrough Therapy Designation based on clinically meaningful, rapid more...
Corstasis Therapeutics and Cardiovascular Logistics Partner to Redefine Outpatient Heart Failure Care with ENBUMYST™ (Bumetanide Nasal Spray)
HENDERSON, Nev.--(BUSINESS WIRE)--#CHF--Corstasis Therapeutics Inc., a commercial-stage biopharmaceutical company advancing innovative outpatient therapies for cardiovascular and renal disease, today announced that it is working with Cardiovascular Logistics (CVL) to support the clinical adoption and integration more...
With Two in Five Employees Undergoing Fertility Treatment Leaving Their Jobs or Considering Quitting, Are Companies Doing Enough?
SAINT-PREX, Switzerland--(BUSINESS WIRE)--An international survey, spanning Australia, France, Japan, Poland and the UK, has found that many employees experiencing fertility challenges lack support in the workplace, with almost two in five (39%) leaving or considering more...
Otsuka Receives FDA Accelerated Approval for VOYXACT® (sibeprenlimab-szsi) for the Reduction of Proteinuria in Adults with Primary Immunoglobulin A Nephropathy (IgAN) at Risk for Disease Progression
VOYXACT achieved a significant placebo-adjusted treatment effect of 51% (P<0.0001) reduction in proteinuria at 9 months of treatment (-50% VOYXACT vs 2% placebo) in the VISIONARY Phase 3 interim analysis. In the study, the most more...
Align Technology Recognized for the 3rd Time in Extel’s 2025 All-America Executive Team Rankings, Including the Most Honored Company Distinction
Company, board of directors, and executives earns multiple #1, #3 and top 10 rankings across leadership, governance, and investor relations categories in the Health Care Technology & Distribution sector and Large-Cap ($10B–$50B) market segment TEMPE, more...
Alkermes to Participate in Two Upcoming Investor Conferences
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. 8th Annual Evercore Healthcare Conference Date/Time: Wednesday, Dec. 3, 2025 at 2:10 p.m. ET (7:10 p.m. GMT) Piper Sandler more...
Jay & Raman Bhaumik Announce Thesis Pharmacy Rebranding from Texas Star, Signaling Precision Growth and National Expansion
The pharmacy, a national compounding leader, unveils its Thesis brand, emphasizing scientific rigor, personalized medicine, and compassionate care. PLANO, Texas--(BUSINESS WIRE)--Thesis Pharmacy today announced its official rebrand from Texas Star Pharmacy, marking a major milestone more...
Capital Equilibrium Launches a New Level-Funded Pharmacy Benefit Program Powered by Capital Rx
Leveraging Capital Rx’s spread-free, full pass-through pharmacy benefit model, Capital Equilibrium is bringing Rx cost savings and renewal stability to the self-funded municipality and commercial markets NEW YORK--(BUSINESS WIRE)--Capital Rx, Judi Health’s transparent pharmacy benefit more...
Momcozy Unveils Exclusive Black Friday Deals on Everyday Essentials for Mothers and Babies
Momcozy is delivering exceptional savings across babycare products this shopping season NEW YORK--(BUSINESS WIRE)--Momcozy, a global leader in maternal and baby care, is excited to unveil its exclusive deals for the Black Friday season in more...
Real-World Evidence [RWE] Demonstrates Repatha’s Long-Term Cardiovascular Benefits
RWE Supports Repatha’s Effectiveness in Reducing Major Adverse Cardiovascular Events (MACE) in Patients with ASCVD Data Presented at American Heart Association Scientific Sessions 2025 DURHAM, N.C.--(BUSINESS WIRE)--#ASCVD--Target RWE, a leader in advancing modern evidence generation more...
Median Technologies to Showcase AI-Powered Software as a Medical Device eyonis® LCS for Lung Cancer Screening at the RSNA 2025 Annual Meeting
Peer-reviewed scientific presentation: "Rethinking Lung Cancer Screening: Longitudinal AI/ML Diagnostics beyond Nodule Size Growth” AI Theater Presentation: "eyonis® LCS: Transforming Lung Cancer Screening Through AI-Powered Early Detection & Diagnosis” Median iCRO & eyonis® teams will more...
Court Finds That Two Advanced Cell Diagnostics Patents Are Not Infringed by Molecular Instruments’ Proprietary HCR™ RNA-ISH Technology
LOS ANGELES--(BUSINESS WIRE)--#Biotech--Molecular Instruments, Inc. announced today that the Unified Patent Court (UPC) of the European Union has found that Molecular Instruments’ HCR™ RNA-ISH technology does not infringe two patents owned by Advanced Cell Diagnostics, more...
Vagaro Launches Free Tool to Help Business Owners Assess Business Health
Powered by Vagaro’s industry insights, the free assessment helps beauty, wellness, and fitness professionals benchmark performance and uncover opportunities for growth. SAN FRANCISCO--(BUSINESS WIRE)--Vagaro, the leading software for businesses in beauty, wellness, and fitness, today more...
Otsuka Pharmaceutical Submits New Drug Application to U.S. FDA for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults
Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents, and adults. It is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI). In four pivotal Phase 3 clinical trials evaluating the more...
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
In the TRANSCEND MCL trial, 82.7% of patients responded to Breyanzi, with 71.6% of patients achieving complete response Breyanzi demonstrated sustained clinical benefit, with 50.8% of patients still in response at 24 months based on more...
Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium
First clinical validation of the Oncodetect ® test to be presented in triple negative breast cancer; signals highly sensitive molecular residual disease (MRD) detection The Oncotype DX® test is associated with improved outcomes and lower more...
Artera Unveils Data Demonstrating Prognostic and Predictive Utility in Breast Cancer at SABCS 2025
First multi-country study validates AI model for risk stratification and chemotherapy predictionSAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced that three abstracts will be presented at more...
MedTech Innovator Announces the 2025 Mid-Stage Grand Prize and Value Award Winners
—Powerful Medical wins $200,000 Grand Prize, recognizing its AI electrocardiogram (ECG) diagnostics and care-coordination platform with two times the sensitivity on heart attacks compared to the current standard of care— —Wavelet named the Value Award more...
CORRECTING and REPLACING Pathway to Cures Invests in SeraGene Therapeutics
NEW YORK--(BUSINESS WIRE)--Fifth paragraph of release dated November 19, 2025, should read: Pathway to Cures joins Hextwo Capital as early investors in SeraGene Therapeutics. The updated release reads: PATHWAY TO CURES INVESTS IN SERAGENE THERAPEUTICS more...
SHORE Study Demonstrates HeartCare’s Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation
Third SHORE Publication Highlights HeartCare’s Role in Risk Stratification and Personalized Post-Transplant Care SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and commercialization of more...
Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to more...
Arcturus Therapeutics to Attend Upcoming Investor Conference
SAN DIEGO--(BUSINESS WIRE)--$ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced more...
BioCorteX Announces Strategic Partnership with CD Biopharma of China
UK company’s high tech expertise allows for accelerated development of anti-cancer drugs aimed at solid tumors BioCorteX Carbon Mirror platform increases the likelihood of trial successLONDON--(BUSINESS WIRE)--BioCorteX, the UK-based pioneering tech bio company, said Wednesday more...
Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention
Not intended for UK Media OCEANIC-STROKE demonstrates superiority of asundexian with antiplatelet therapy, showing significant reduction in ischemic stroke risk, without increasing ISTH major bleeding rate, compared to placebo with antiplatelet therapy OCEANIC-STROKE is the more...
Transmural Systems Receives FDA 510(k) Clearance for TELLTALE
ANDOVER, Mass.--(BUSINESS WIRE)--Transmural Systems, a leader in pioneering electrosurgical structural heart therapies, obtained 510(k) clearance from the United States Food and Drug Administration (FDA) for TELLTALE – the first and only cleared and dedicated electrosurgical more...